Kisho is an information platform, not a medical provider. Nothing on this site constitutes medical advice, diagnosis, or treatment recommendations. All content is aggregated from publicly available sources (including ClinicalTrials.gov, PubMed, FDA.gov, and Orphanet) and is provided for informational purposes only. Clinical trial eligibility, treatment decisions, and any health-related actions should always be discussed with a qualified healthcare professional. Kisho does not endorse any specific therapy, organization, or clinical trial. Terms of use · Privacy policy
Any retinitis pigmentosa in which the cause of the disease is a mutation in the FAM161A gene.
Features include: Constriction of peripheral visual field, Bone spicule pigmentation of the retina, Nyctalopia, and Rod-cone dystrophy and 1 more.
Organ System | Phenotype Count | Example Features |
|---|---|---|
Bones and joints | 1 | Bone spicule pigmentation of the retina |
FAM161A encodes FAM161 centrosomal protein A (660 aa). Involved in ciliogenesis Highest expression in Testis (15.7 TPM) and Ovary (10.0 TPM).
Retinitis pigmentosa 28 is associated with mutations in the FAM161A gene on chromosome 2.
FAM161A is classified as a druggable target with score 0.0.
Genetic testing for FAM161A is available. Testing is considered confirmatory for diagnosis.
No clinical trials have been registered for retinitis pigmentosa 28.
16 publications have been identified in PubMed for retinitis pigmentosa 28. Research spans Basic Science / Preclinical (56%), Case Report / Case Series (13%), and Clinical Trial Publication (13%).
Research Type | Count | % of Total |
|---|---|---|
Laboratory research | 9 | 56% |
Data assembled from 5 of 12 sources · Last updated Sep 19, 2026, 2:53 PM UTC
Online Mendelian Inheritance in Man
Genetic and Rare Diseases Info Center
1 |
Optic disc pallor |
2 |
13% |
Clinical study results | 2 | 13% |
Disease patterns and progression | 2 | 13% |
Research summaries | 1 | 6% |
Alhamad J (2026). [PMID: 42009625](https://pubmed.ncbi.nlm.nih.gov/42009625/). *Ophthalmic Genet*. [Case Report / Case Series]
Karuntu JS (2026). [PMID: 40530429](https://pubmed.ncbi.nlm.nih.gov/40530429/). *Acta Ophthalmol*. [Clinical Trial Publication]
Ferch M (2025). [PMID: 40302276](https://pubmed.ncbi.nlm.nih.gov/40302276/). *J Clin Endocrinol Metab*. [Case Report / Case Series]
Heyang M (2025). [PMID: 39103200](https://pubmed.ncbi.nlm.nih.gov/39103200/). *Br J Ophthalmol*. [Epidemiology / Natural History]
Bubis E (2025). [PMID: 40528096](https://pubmed.ncbi.nlm.nih.gov/40528096/). *Graefes Arch Clin Exp Ophthalmol*. [Basic Science / Preclinical]
Fernandez-Gonzalez P (2025). [PMID: 41052560](https://pubmed.ncbi.nlm.nih.gov/41052560/). *Int J Biol Macromol*. [Basic Science / Preclinical]
Liu H (2025). [PMID: 39804630](https://pubmed.ncbi.nlm.nih.gov/39804630/). *Invest Ophthalmol Vis Sci*. [Basic Science / Preclinical]
Haqq AM (2025). [PMID: 39919037](https://pubmed.ncbi.nlm.nih.gov/39919037/). *J Clin Endocrinol Metab*. [Clinical Trial Publication]
Li S (2024). [PMID: 38754567](https://pubmed.ncbi.nlm.nih.gov/38754567/). *Gene*. [Basic Science / Preclinical]
Tzaridis S (2024). [PMID: 39601967](https://pubmed.ncbi.nlm.nih.gov/39601967/). *Angiogenesis*. [Basic Science / Preclinical]